Accelerated Medical Diagnostics
AMD is developing PlatinDx, a diagnostic test to predict sensitivity towards platinum based chemotherapeutics.

The Story:


Founded in 2008, Accelerated Medical Diagnostics, Inc., is a cancer diagnostics company with offices located in Dublin, CA and laboratory facilities in Davis, CA. At Accelerated Medical Diagnostics, we fuse expertise in cancer biology, drugs and diagnostics to develop objective, reproducible tests that provide clinicians with information to enhance patient care.

As a pioneer in the field of predictive chemotherapy diagnostics, the company is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on platinum-based chemotherapy for bladder, lung and breast cancer, Accelerated Medical Diagnostics is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of our test, called PlatinDx, which measures cellular responses to nontoxic “microdoses” of chemotherapy administered to patients.

Chemotherapy drugs that target DNA, such as the platinum-based class of alkylating agents, chemically modify the DNA such that cellular replication is inhibited.  This process retards tumor growth and causes cell death.  However, some tumors tolerate the drugs much better than others via a variety of complex mechanisms.  Platinum-based drugs cure some patients, while many others do not respond at all.  The PlatinDx assay is being developed to predict tumor capacity to tolerate exposure to platinum drugs and predict efficacy of the therapy for individual patients.

PlatinDx is based upon the measurement of a drug-DNA adduct frequency ratio obtained in a microdosing setting—a nontoxic approach for quantifying cellular responses to chemotherapy in vivo. PlatinDX requires the patient be exposed intravenously to a sub-therapeutic dose, called a microdose, which is 1% of the therapeutic dose of a platinum-based anti-cancer agent.   This dose is low enough so as to be safe for patients, but sufficient to allow measurement of drug-DNA damage formation in tumors.

With time, the drug enters the tumor cells and forms drug-DNA damage, which we can measure the with a proprietary mass spectrometry protocol. The resulting information can be used by physicians to decide whether subsequent full-dose chemotherapy is appropriate for that patient.

Accelerated Medical Diagnostics is currently conducting clinical studies aimed proving the PlatinDx concept in the clinic, obtaining regulatory approval and gaining reimbursement from payers.

Accelerated Medical Diagnostics is a privately held company funded predominantly by research contracts.  We are developing the PlatinDx test through collaborations with university hospitals.  Accelerated Medical Diagnostics is currently conducting two feasibility clinical trials with collaborators at UC Davis, UCLA, UCSF and USC.